Abstract:Mutations in mitochondrial (mt)DNA are associated with severe disorders for which treatment is currently limited; this study shows that mtDNA mutations can be genetically corrected and normal metabolic function restored in cells derived from patients with mtDNA disease and reprogrammed to pluripotency through factor-mediated reprogramming or via a somatic cell nuclear transfer approach. Mutations in mitochondrial (mt)DNA are associated with severe disorders for which treatment is currently limited. This study demonstrates that mtDNA mutations can be genetically corrected and normal metabolic function restored in skin fibroblasts derived from patients with mtDNA disease using pluripotent stem cells derived by both factor-meditated reprogramming (iPS cells) and somatic cell nuclear transfer (SCNT) approaches. Mitochondria have a major role in energy production via oxidative phosphorylation1, which is dependent on the expression of critical genes encoded by mitochondrial (mt)DNA. Mutations in mtDNA can cause fatal or severely debilitating disorders with limited treatment options2. Clinical manifestations vary based on mutation type and heteroplasmy (that is, the relative levels of mutant and wild-type mtDNA within each cell)3,4. Here we generated genetically corrected pluripotent stem cells (PSCs) from patients with mtDNA disease. Multiple induced pluripotent stem (iPS) cell lines were derived from patients with common heteroplasmic mutations including 3243A>G, causing mitochondrial encephalomyopathy and stroke-like episodes (MELAS)5, and 8993T>G and 13513G>A, implicated in Leigh syndrome. Isogenic MELAS and Leigh syndrome iPS cell lines were generated containing exclusively wild-type or mutant mtDNA through spontaneous segregation of heteroplasmic mtDNA in proliferating fibroblasts. Furthermore, somatic cell nuclear transfer (SCNT) enabled replacement of mutant mtDNA from homoplasmic 8993T>G fibroblasts to generate corrected Leigh-NT1 PSCs. Although Leigh-NT1 PSCs contained donor oocyte wild-type mtDNA (human haplotype D4a) that differed from Leigh syndrome patient haplotype (F1a) at a total of 47 nucleotide sites, Leigh-NT1 cells displayed transcriptomic profiles similar to those in embryo-derived PSCs carrying wild-type mtDNA, indicative of normal nuclear-to-mitochondrial interactions. Moreover, genetically rescued patient PSCs displayed normal metabolic function compared to impaired oxygen consumption and ATP production observed in mutant cells. We conclude that both reprogramming approaches offer complementary strategies for derivation of PSCs containing exclusively wild-type mtDNA, through spontaneous segregation of heteroplasmic mtDNA in individual iPS cell lines or mitochondrial replacement by SCNT in homoplasmic mtDNA-based disease.

MitoTALEN reduces mutant mtDNA load and restores tRNAAla levels in a mouse model of heteroplasmic mtDNA mutation

mitoTALEN Reduces the Mutant mtDNA Load in Neurons

Mutations in MTO2 Related to Trna Modification Impair Mitochondrial Gene Expression and Protein Synthesis in the Presence of a Paromomycin Resistance Mutation in Mitochondrial 15 S Rrna

Correction for Li and Guan, “human Mitochondrial Leucyl-tRNA Synthetase Corrects Mitochondrial Dysfunctions Due to the Trnaleu(uur) A3243G Mutation, Associated with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Symptoms and Diabetes”

Targeted Elimination of Mutant Mitochondrial DNA in MELAS-iPSCs by Mitotalens

A Coronary Artery Disease-Associated Trna(thr) Mutation Altered Mitochondrial Function, Apoptosis and Angiogenesis

Identification and Characterization of Mouse MTO1 Gene Related to Mitochondrial Trna Modification.

Nuclear Modifier Mto2 Modulates The Aminoglycoside-Sensitivity Of Mitochondrial 15s Rrna C1477g Mutation In Saccharomyces Cerevisiae

Multilevel Functional and Structural Defects Induced by Two Pathogenic Mitochondrial Trna Mutations

Overexpression of Human Mitochondrial Alanyl-Trna Synthetase Suppresses Biochemical Defects of the Mt-Trna(ala) Mutation in Cybrids

Mitochondrial Transplantation Therapy Ameliorates Muscular Dystrophy in mdx Mouse Model

In vivo mitochondrial base editing via adeno-associated viral delivery to mouse post-mitotic tissue

Mitochondrial haplotype mutation alleviates respiratory defect of MELAS by restoring taurine modification in tRNA with 3243A > G mutation

Consequences of Zygote Injection and Germline Transfer of Mutant Human Mitochondrial DNA in Mice

Gene therapy restores mitochondrial function and protects retinal ganglion cells in optic neuropathy induced by a mito-targeted mutant ND1 gene

Overexpression of human mitochondrial alanyl-tRNA synthetase suppresses biochemical defects of the mt-tRNAAla mutation in cybrids

Metabolic Rescue in Pluripotent Cells from Patients with Mtdna Disease

Amelioration of Leigh syndrome induced by mouse blastocyst complementation with a mutant human mitochondrial ATP synthase 6

Reduction of mtDNA heteroplasmy in mitochondrial replacement therapy by inducing forced mitophagy

Transgenic mouse model with deficient mitochondrial polymerase exhibits reduced state IV respiration and enhanced cardiac fibrosis

High-Efficiency And Heritable Gene Targeting In Mouse By Transcription Activator-Like Effector Nucleases